首页> 外文OA文献 >Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

【2h】

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

机译：从Rituximab切换到类风湿性关节炎中的生物仿制性CT-P10的功效和安全性：随机阶段3试验中的72周数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Seung Cheol Shim; Ljubinka Božić-Majstorović; Alfredo Berrocal Kasay; Elias Chalouhi El-Khouri; Fedra Irazoque-Palazuelos; Francisco Fidencio Cons Molina; Francisco G Medina-Rodriguez; Pedro Miranda; Pavel Shesternya; Jose Chavez-Corrales; Piotr Wiland; Slawomir Jeka; Olena Garmish; Pawel Hrycaj; Natalia Fomina; Won Park; Chang-Hee Suh; Sang Joon Lee; Sung Young Lee; Yun Ju Bae; Dae Hyun Yoo;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial [J] . Shim Seung Cheol, Bozic-Majstorovic Ljubinka, Kasay Alfredo Berrocal, Rheumatology . 2019,第12期

机译：从Rituximab切换到类风湿性关节炎中的生物仿制性CT-P10的功效和安全性：随机阶段3试验中的72周数据
2. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial [J] . Yoo Dae Hyun, Suh Chang-Hee, Shim Seung Cheol, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2017,第4期

机译：高达两种疗程的疗效，安全性和药代动力学在类风湿性关节炎患者中患者的毒素蛋白生物仿生CT-P10与Innovator Rituximab的疗效，安全性和创新者Rituximab：结果最多为一期随机对照试验的第72周
3. Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial [J] . Suh Chang-Hee, Yoo Dae Hyun, Berrocal Kasay Alfredo, BioDrugs: Clinical immunotherapeutics, biopharmaceuticals, and gene therapy . 2019,第1期

机译：生物仿制性CT-P10的长期疗效和安全性与风湿性关节炎中的创新者Rituximab：随机期III试验的48周结果
4. Identification of candidate genes for Rituximab response in rheumatoid arthritis with weighted gene co-expression network analysis [C] . Guiying Dong, Zhi-Ping Liu, Rui Gao, Chinese Automation Congress . 2017

机译：用加权基因共表达网络分析鉴定类风湿关节炎中利妥昔单抗反应的候选基因
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial [O] . Dae Hyun Yoo, Chang-Hee Suh, Seung Cheol Shim, -1

机译：类风湿关节炎患者中多达两个疗程的利妥昔单抗生物仿制药CT-P10与创新药物利妥昔单抗的疗效安全性和药代动力学：截至第一阶段随机对照试验第72周的结果
7. Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis [O] . Won Park, Chang-Hee Suh, Seung Cheol Shim, 2017

机译：与CT-P10的持续治疗相比，从创新者Rituximab切换到生物仿制性CT-P10的功效和安全性：试验性关节炎患者的56周开放标签研究结果

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

著录项

引文网络

相似文献

相关主题

期刊订阅